Log in

OTCMKTS:NEVPFNeuroVive Pharmaceutical Stock Price, Forecast & News

$0.08
-0.03 (-24.17 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.08
Now: $0.08
$0.08
50-Day Range
$0.08
MA: $0.12
$0.16
52-Week Range
$0.06
Now: $0.08
$0.31
Volume1,111 shs
Average Volume25,610 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta1.42
NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial medicine in Sweden and internationally. Its product portfolio includes NeuroSTAT, a drug candidate that is in phase II clinical trial for the treatment of traumatic brain injuries; and KL1333 that is in phase I clinical trial for the treatment of genetic mitochondrial diseases. The company also develops NVP015/NV354 drug candidates for mitochondrial diseases; NVP025 drug candidate for mitochondrial myopathies; NV556 and NVP022 drug candidates for non-alcoholic steatohepatitis conditions; and NVP024, a hepatocellular carcinoma program. NeuroVive Pharmaceutical AB (publ) has collaboration agreements with Isomerase Therapeutics, Sihuan Pharmaceutical, and Sanofi Korea. The company also has a preclinical collaboration agreement with the Children's Hospital of Philadelphia for research in genetic mitochondrial disorders. NeuroVive Pharmaceutical AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NEVPF
CUSIPN/A
CIKN/A
Phone46-4-627-562-20

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.21 per share

Profitability

Miscellaneous

Employees7
Next Earnings Date8/19/2020 (Estimated)
OptionableNot Optionable

Receive NEVPF News and Ratings via Email

Sign-up to receive the latest news and ratings for NEVPF and its competitors with MarketBeat's FREE daily newsletter.

NeuroVive Pharmaceutical (OTCMKTS:NEVPF) Frequently Asked Questions

How has NeuroVive Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

NeuroVive Pharmaceutical's stock was trading at $0.0796 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NEVPF stock has increased by 0.5% and is now trading at $0.08. View which stocks have been most impacted by Coronavirus.

When is NeuroVive Pharmaceutical's next earnings date?

NeuroVive Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, August 19th 2020. View our earnings forecast for NeuroVive Pharmaceutical.

Has NeuroVive Pharmaceutical been receiving favorable news coverage?

News articles about NEVPF stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeuroVive Pharmaceutical earned a news impact score of -2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about NeuroVive Pharmaceutical.

Who are some of NeuroVive Pharmaceutical's key competitors?

Who are NeuroVive Pharmaceutical's key executives?

NeuroVive Pharmaceutical's management team includes the following people:
  • Mr. Erik Kinnmann M.D., Ph.D., M.B.A., Assoc. Prof., Chief Exec. Officer (Age 61)
  • Ms. Catharina Jz Johansson, CFO & VP of Investor Relations (Age 52)
  • Dr. Eskil Elmér, Chief Scientific Officer & VP of Discovery (Age 49)
  • Daniel Schale, Director of Communications
  • Dr. Magnus Hansson, Chief Medical Officer and VP of Preclinical & Clinical Devel. (Age 43)

What is NeuroVive Pharmaceutical's stock symbol?

NeuroVive Pharmaceutical trades on the OTCMKTS under the ticker symbol "NEVPF."

How do I buy shares of NeuroVive Pharmaceutical?

Shares of NEVPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NeuroVive Pharmaceutical's stock price today?

One share of NEVPF stock can currently be purchased for approximately $0.08.

What is NeuroVive Pharmaceutical's official website?

The official website for NeuroVive Pharmaceutical is www.neurovive.com.

How can I contact NeuroVive Pharmaceutical?

NeuroVive Pharmaceutical's mailing address is MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 22381. The company can be reached via phone at 46-4-627-562-20 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.